Search results :

Ondansetron

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: A04AA01

Side effects

Options: Hide MedDRA Preferred Terms ,   display all 38 labels

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Wound Wound 10.6% - 27.6% 11.8% - 30.5% x x x x x x x x x
Somnolence Drowsiness 5.43% - 20.4% 6.76% - 23% x x x x x x x x x x x x
Headache Headache very common, 5.83% - 27.2% 5.08% - 15% x x x x x x x x x x x x x x x x x x x x
Musculoskeletal pain Musculoskeletal pain 10.4% 10.8% x
Asthenia Fatigue 2.29% - 13.2% 2.29% - 5.48% x x x x x x x
Asthenia x x
Fatigue Fatigue 2.29% - 13.2% 2.29% - 5.48% x x x x x x x
Malaise Malaise 2.29% - 13.2% 2.29% - 5.48% x x x x x x x
Discomfort Malaise 2.29% - 13.2% 2.29% - 5.48% x x x x x x x
Feeling abnormal Malaise 2.29% - 13.2% 2.29% - 5.48% x x x x x x x
Ill-defined disorder Malaise 2.29% - 13.2% 2.29% - 5.48% x x x x x x x
Hypoxia Hypoxia 8.91% 6.59% x x x x x x x x
Body temperature increased Body temperature increased 1.83% - 8.18% 1.1% - 6.4% x x x x x x x x x x x x x x x
Genital disorder female Genital disorder female 6.55% 6.21% x x x x x x
Constipation Constipation common, 0.382% - 9.09% 0.382% x x x x x x x x x x x x x x x x x x x x
Anxiety Anxiety 2.01% - 6.49% 2.93% - 6.43% x x x x x x x x x x
Agitation Agitation 2.01% - 6.49% 2.93% - 6.43% x x x x x x x x x
Bradycardia Bradycardia postmarketing — 5.82% 5.65% x x x x x x x x x x x x x x x x
Dizziness Dizziness postmarketing — 0.01% - 12.2% 4.58% - 16.1% x x x x x x x x x x x x x x x x
Syncope postmarketing x x x x x x x
Chills Shivering 5.09% - 6.95% 5.65% - 7.13% x x x x x x x x x
Urinary retention Urinary retention 3.11% - 5.09% 2.74% - 3.39% x x x x x x x x x
Dry mouth Dry mouth common x x x x
Anorectal discomfort Burning rectal common x
Feeling hot Sensation of warmth common x x x x
Warmth 1% x x
Hypotension Hypotension postmarketing — 1.83% - 4.91% 2.19% - 6.03% x x x x x x x x x x x x x x x x x x x x
Pruritus Pruritus 1.65% - 4.91% 0.548% - 3.77% x x x x x x x x x x x x
Diarrhoea Diarrhoea 1.79% - 44% 0.898% - 18% x x x x x x x x x x x x x x
Injection site reaction Injection site reaction common, 3.84% 3.29% x x x x x x x x
Chest pain Chest pain postmarketing — 2.19% 2.74% x x x x x x x x x x x x x x x x x x x x
Dysuria Dysuria 2.01% 1.65% x x x
Paraesthesia Paraesthesia 1.65% 0.366% x x x x
Feeling cold Feeling cold 1.65% 1.46% x x x x
Procedural pain Post procedural pain 1.19% 1.8% x
Dyskinesia Dyskinesia uncommon x x x x x
Movement disorder uncommon x x x x x
Orofacial dyskinesia postmarketing x x
Movement disorder Movement disorder uncommon x x x x x
Convulsion Convulsion uncommon x x x x x x
Liver function test abnormal Raised liver function tests postmarketing, uncommon x x x
Anaphylactic shock Anaphylactic shock postmarketing, rare x x x x x x x x x x x x x x x x
Anaphylactoid reaction x x x x x x x x
Angina pectoris Angina pectoris postmarketing x x x x x x x x x x x x x x x x
Angioedema Angioedema postmarketing x x x x x x x x x x x x x x
Arrhythmia Arrhythmia postmarketing, uncommon x x x x x x x x x x x
Atrial fibrillation Atrial fibrillation postmarketing x x x x x x x
Bronchospasm Bronchospasm postmarketing, 0.595% 1.8% x x x x x x x x x x x x x x x x
Neoplasm malignant Neoplasm malignant postmarketing x x
Cardiovascular disorder Cardiovascular disorder postmarketing x x
Dyspnoea Dyspnoea postmarketing x x x x x x x x x x x x
Toxic epidermal necrolysis Toxic epidermal necrolysis very rare, postmarketing x x x x
Eye disorder Eye disorder postmarketing x x x x x x x x x x x x x x
Flushing Flushing postmarketing, common x x x x x x x x x x x x x x x x x x
Hiccups Hiccups postmarketing, uncommon x x x x x x x x x x x x x x x x x x
Hypersensitivity Hypersensitivity postmarketing x x x x x x x x x x x x x x
Type I hypersensitivity Type I hypersensitivity rare x x x x x x
Laryngeal oedema Laryngeal oedema postmarketing x x x x x x x x x x x x x x
Laryngospasm Laryngospasm postmarketing x x x x x x x x x x x x x x x
Mediastinal disorder Mediastinal disorder postmarketing x x x x x x
Myocardial infarction Myocardial infarction postmarketing x x
Acute coronary syndrome Myocardial infarction postmarketing x x
Nervous system disorder Nervous system disorder postmarketing x x x x x x
Pain Pain postmarketing, 2.19% 2.93% x x x x x x x
Palpitations Palpitations postmarketing x x x x x x x
Shock Shock postmarketing x x x x x x x x x x x x
Syncope postmarketing x x x x x x x
Erythema multiforme Stevens-Johnson syndrome postmarketing x x x
Stevens-Johnson syndrome Stevens-Johnson syndrome postmarketing x x x
Stridor Stridor postmarketing x x x x x x x x x x x x x x
Syncope Syncope postmarketing x x x x x x x
Loss of consciousness Syncope postmarketing x x x x x x x
Supraventricular tachycardia Supraventricular tachycardia postmarketing x x x x x x x
Torsade de pointes Torsade de pointes rare x x x
Tremor Tremor postmarketing x x
Urticaria Urticaria postmarketing x x x x x x x x x x x x x x
Angiopathy Angiopathy rare x x x x
Vomiting Vomiting postmarketing
Hepatic failure Hepatic failure postmarketing x x x x x x x x x x x x x x
Oculogyric crisis Oculogyric crisis postmarketing, uncommon x x x x x x x x x x x x x x x x x x
Ventricular extrasystoles Ventricular extrasystoles postmarketing x x x x x x x
Myocardial ischaemia Myocardial ischaemia postmarketing x x
Opisthotonus Opisthotonus postmarketing x x
Accommodation disorder Accommodation disorder postmarketing x x x x x
Blindness transient Blindness transient very rare, postmarketing x x x x x x x x x x x x x x x x x
Atrioventricular block second degree Atrioventricular block second degree postmarketing x x x x x x x
Hepatobiliary disease Hepatobiliary disease postmarketing x x x x x x
Erythema Redness postmarketing x x x x x
Vision blurred Vision blurred postmarketing x x x x x x x x x x
Blindness Blindness postmarketing x x x x x x
Electrocardiogram ST segment depression Electrocardiogram ST segment depression postmarketing, uncommon x x x x x x x x x x x
Procedural nausea Nausea postoperative postmarketing
Injection site pain Injection site burning postmarketing x x x x x
Dystonia Dystonic reaction postmarketing — 0% - 5% 0% x x x x x x x x x x x x x x x x x x x x
Visual impairment Visual disturbance rare x x x x x
Cardio-respiratory arrest Cardio-respiratory arrest postmarketing x x x x x x x x x x x x x
Local reaction Local reaction postmarketing x x x x x x
Electrocardiogram QT prolonged Electrocardiogram QT corrected interval prolonged rare x x x
Lymphocyte transformation test positive Lymphocyte transformation test positive postmarketing x x x
Toxic skin eruption Toxic skin eruption very rare x
Abdominal pain Abdominal pain x x x x
Gastrointestinal pain Abdominal pain x x x x
Asthma Asthma x x
Cough Cough x x
Ear disorder Ear disorder x x
Dermatitis Rash x x x x x x x x x x x x x x x x x x
Rash Rash x x x x x x x x x x x x x x x x x x
Flatulence Flatulence x x
Gastrointestinal disorder Gastrointestinal disorder x x x x
Cardiac disorder Cardiac disorder x x x x
Haemorrhage Haemorrhage x x
Haemoglobin Haemorrhage x x
Hypokalaemia Hypokalaemia x x x x x x x x x x x x x x x x
Immune system disorder Immune system disorder x x x x
Liver disorder Liver disorder x x x x x x x x x x x x x x
Hepatocellular injury Liver disorder x x x x x x x x x x x x x x
Foetor hepaticus Liver disorder x x x x x x x x x x x x x x
Sleep disorder Sleep disturbance x x
Swelling Swelling x x
Tachycardia Tachycardia x x x x x x x x x x x x x x x x
Urinary tract infection Urinary tract infection x x
Aspartate aminotransferase increased Aspartate aminotransferase increased x x
Skin disorder Unspecified disorder of skin and subcutaneous tissue x
Anaphylactoid reaction Anaphylactoid reaction x x x x x x x x
Akathisia Akathisia 0% - 6% 0% x x x
Grand mal convulsion Tonic-clonic seizures x x x x x x x x x x x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

ondansetron

Side effects:14
Source:FDA Structured Product Label

ondansetron

Side effects:14
Source:FDA Structured Product Label

ONDANSETRON

Side effects:34
Source:FDA Structured Product Label

ONDANSETRON

Side effects:39
Source:FDA Structured Product Label

ONDANSETRON / ZOFRAN ODT

Side effects:42
Source:FDA

ONDANSETRON

Side effects:43
Source:FDA Structured Product Label

Ondansetron

Side effects:44
Source:FDA Structured Product Label

ONDANSETRON

Side effects:44
Source:FDA Structured Product Label

ONDANSETRON

Side effects:45
Source:FDA Structured Product Label

ONDANSETRON

Side effects:48
Source:FDA Structured Product Label

ONDANSETRON

Side effects:49
Source:FDA Structured Product Label

ONDANSETRON

Side effects:52
Source:FDA Structured Product Label

ONDANSETRON

Side effects:55
Source:FDA Structured Product Label

Ondansetron (as hydrochloride dihydrate) / ONDANSETRON

Side effects:59
Source:medicines.org.au

Ondansetron

Side effects:61
Source:FDA Structured Product Label

Color scheme:

standardalternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label